Nimbus Therapeutics said it has raised $210 million in venture capital to advance its pipeline of drugs to combat other disorders, including cancer. Seven months ago, the Boston-based biotech sold an experimental autoimmune disease medicine to Takeda Pharmaceuticals for up to $6 billion. (The Boston Globe)

Johnson & Johnson announced that it is stopping a Phase 3 study evaluating its pulmonary arterial hypertension drug in patients with chronic thromboembolic pulmonary hypertension. The decision to end the CTEPH study, due to futility, was made at the recommendation of the study’s independent data monitoring committee following a pre-planned interim analysis. (Zacks)

Pfizer and French pharmaceutical peer Valneva announced that a Phase 2 study for its VLA15 Lyme disease vaccine candidate showed a “strong immune response” in both children and adolescents a month after a booster shot. “The Phase 2 booster results emphasize the vaccine candidate’s potential to provide immunity against Lyme disease in pediatric and adolescent populations,” the two companies said in a statement. (Reuters)

Mariana Oncology, a startup working to make radiation treatment more precise for certain cancers, completed a $175 million financing round. The equity investment comes from Eli Lilly and Co., among other investors. (Boston Business Journal)

Kourtney Kardashian spoke out about undergoing “urgent fetal surgery” to save her unborn baby’s life. “As someone who has had three really easy pregnancies in the past, I wasn’t prepared for the fear of rushing into urgent fetal surgery,” she wrote on Instagram. “I don’t think anyone who hasn’t been through a similar situation can begin to understand that feeling of fear.” (NBC News)